Literature DB >> 28154185

Heterochromatin Protein 1γ Is a Novel Epigenetic Repressor of Human Embryonic ϵ-Globin Gene Expression.

Yadong Wang1, Ying Wang1, Lingling Ma1, Min Nie1, Junyi Ju1, Ming Liu1, Yexuan Deng1, Bing Yao1, Tao Gui1, Xinyu Li1, Chan Guo1, Chi Ma1, Renxiang Tan1, Quan Zhao2.   

Abstract

Production of hemoglobin during development is tightly regulated. For example, expression from the human β-globin gene locus, comprising β-, δ-, ϵ-, and γ-globin genes, switches from ϵ-globin to γ-globin during embryonic development and then from γ-globin to β-globin after birth. Expression of human ϵ-globin in mice has been shown to ameliorate anemia caused by β-globin mutations, including those causing β-thalassemia and sickle cell disease, raising the prospect that reactivation of ϵ-globin expression could be used in managing these conditions in humans. Although the human globin genes are known to be regulated by a variety of multiprotein complexes containing enzymes that catalyze epigenetic modifications, the exact mechanisms controlling ϵ-globin gene silencing remain elusive. Here we found that the heterochromatin protein HP1γ, a multifunctional chromatin- and DNA-binding protein with roles in transcriptional activation and elongation, represses ϵ-globin expression by interacting with a histone-modifying enzyme, lysine methyltransferase SUV4-20h2. Silencing of HP1γ expression markedly decreased repressive histone marks and the multimethylation of histone H3 lysine 9 and H4 lysine 20, leading to a significant decrease in DNA methylation at the proximal promoter of the ϵ-globin gene and greatly increased ϵ-globin expression. In addition, using chromatin immunoprecipitation, we showed that SUV4-20h2 facilitates the deposition of HP1γ on the ϵ-globin-proximal promoter. Thus, these data indicate that HP1γ is a novel epigenetic repressor of ϵ-globin gene expression and provide a potential strategy for targeted therapies for β-thalassemia and sickle cell disease.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  DNA methylation; H4K20me3; HP1γ; SUV4–20h2; chromatin; gene transcription; hemoglobin; histone methylation

Mesh:

Substances:

Year:  2017        PMID: 28154185      PMCID: PMC5377797          DOI: 10.1074/jbc.M116.768515

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

Review 1.  Locus control regions.

Authors:  Qiliang Li; Kenneth R Peterson; Xiangdong Fang; George Stamatoyannopoulos
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

2.  Histone H3 lysine 9 trimethylation and HP1γ favor inclusion of alternative exons.

Authors:  Violaine Saint-André; Eric Batsché; Christophe Rachez; Christian Muchardt
Journal:  Nat Struct Mol Biol       Date:  2011-02-27       Impact factor: 15.369

Review 3.  Fetal globin gene repressors as drug targets for molecular therapies to treat the β-globinopathies.

Authors:  Mikiko Suzuki; Masayuki Yamamoto; James Douglas Engel
Journal:  Mol Cell Biol       Date:  2014-07-14       Impact factor: 4.272

Review 4.  Mechanisms of heterochromatin subnuclear localization.

Authors:  Benjamin D Towbin; Adriana Gonzalez-Sandoval; Susan M Gasser
Journal:  Trends Biochem Sci       Date:  2013-06-06       Impact factor: 13.807

5.  PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing.

Authors:  Quan Zhao; Gerhard Rank; Yuen T Tan; Haitao Li; Robert L Moritz; Richard J Simpson; Loretta Cerruti; David J Curtis; Dinshaw J Patel; C David Allis; John M Cunningham; Stephen M Jane
Journal:  Nat Struct Mol Biol       Date:  2009-02-22       Impact factor: 15.369

6.  A human embryonic hemoglobin inhibits Hb S polymerization in vitro and restores a normal phenotype to mouse models of sickle cell disease.

Authors:  Zhenning He; J Eric Russell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-17       Impact factor: 11.205

7.  Heterochromatin protein 1gamma epigenetically regulates cell differentiation and exhibits potential as a therapeutic target for various types of cancers.

Authors:  Masakatsu Takanashi; Kosuke Oikawa; Koji Fujita; Motoshige Kudo; Masao Kinoshita; Masahiko Kuroda
Journal:  Am J Pathol       Date:  2008-12-04       Impact factor: 4.307

Review 8.  Therapeutic approaches to hemoglobin switching in treatment of hemoglobinopathies.

Authors:  J A Stamatoyannopoulos; A W Nienhuis
Journal:  Annu Rev Med       Date:  1992       Impact factor: 13.739

Review 9.  Epigenetic regulation of fetal globin gene expression in adult erythroid cells.

Authors:  Gordon D Ginder
Journal:  Transl Res       Date:  2014-05-11       Impact factor: 7.012

10.  Comparison of DNA methylation profiles in human fetal and adult red blood cell progenitors.

Authors:  Samuel Lessard; Mélissa Beaudoin; Karim Benkirane; Guillaume Lettre
Journal:  Genome Med       Date:  2015-01-20       Impact factor: 11.117

View more
  1 in total

1.  LncRNA LINC00998 inhibits the malignant glioma phenotype via the CBX3-mediated c-Met/Akt/mTOR axis.

Authors:  Haiping Cai; Yanjiao Yu; Xiangrong Ni; Cong Li; Yuanjun Hu; Jing Wang; Furong Chen; Shaoyan Xi; Zhongping Chen
Journal:  Cell Death Dis       Date:  2020-12-02       Impact factor: 8.469

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.